TOTAL ALLERGY CARE for HEALTH PROFESSIONALS
Visit RhinocortProfessional.com for information about RHINOCORT® Allergy Spray resources.
to order samples and resources with ZYRTEC ZIPLINE®.

About ZYRTEC®

Start with ZYRTEC® as your foundation for consistent relief1

Whether it’s itchy, watery eyes or runny, itchy noses, ZYRTEC® has patients’ allergy symptoms covered—with fast,* effective relief.2,3

*ZYRTEC® 10 mg starts working at hour 1. Based on the first dose on the first day of a 2-day study in 2 pollen chamber studies. Primary endpoint measured mean improvement from baseline in major symptom complex (MSC) severity score. MSC symptoms included runny nose, sniffles, itchy nose, nose blows, sneezes, and watery eyes.
TBD TBD

ZYRTEC® starts working at hour 1 on the first day you take it*2,3

ZYRTEC® delivers long-term, consistent relief1

  • In SAR, relief continued over a 2- to 4-week treatment period†4
  • In PAR, relief continued over a 4- to 8-week treatment period‡5

ZYRTEC® provides relief that patients can start and stay with

  • ZYRTEC® is generally well tolerated
  • Discontinuation due to adverse events in clinical trials was not significantly different between ZYRTEC® and placebo (2.9% vs 2.4%, respectively)
    • In clinical trials, 14% of patients taking ZYRTEC® 10 mg reported somnolence (n=2034) vs 6% with placebo (n=1612)1
    • In clinical trials, 1% of patients discontinued due to somnolence1

ZYRTEC® significantly improves quality of life (QoL)1,6

Patients receiving ZYRTEC® reported significantly greater improvements in overall RQLQ scores compared with placebo

ZYRTEC® contains cetirizine, an established molecule for effective allergy relief1

Compare ZYRTEC® vs Xyzal® and other OTC oral antihistamines

ZYRTEC® is the #1 Allergist-recommended brand#

#Among OTC oral antihistamines.

ZYRTEC® provides relief for different ages and stages. Learn about Children’s ZYRTEC®

Get expedited shipping on samples and resources with

Learn More

See the ZYRTEC® difference

Compare ZYRTEC® versus other OTC oral antihistamines.

Go

Patient resources for allergy care

Get patient information, counseling tools, plus the ZYRTEC® ALLERGYCAST® app.*

*Standard data rates apply.

See How

†All studies are multicenter, randomized, placebo-controlled, double-blind, minimum 100 participants with previous diagnosis of SAR, and duration (2-4 weeks). Total symptom severity score measured by patient.

‡All studies are multicenter, randomized, placebo-controlled, double-blind, minimum 100 participants with previous diagnosis of PAR, and duration (4-8 weeks). Total symptom response severity score measured by patient.

§Two multicenter, randomized, double-blind, placebo-controlled studies including 1254 adult SAR patients. Primary study endpoint measured changes in overall RQLQ score from baseline.

Multicenter, randomized, double-blind, placebo-controlled study including 316 adult PAR patients. Primary study endpoint measured changes in overall RQLQ score from baseline.

The third-party trademarks used herein are registered trademarks of their respective owners.

References: 1. Data on file, Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division. 2. Day JH, Briscoe M, Widlitz MD. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol. 1998;101(5):638-645. 3. Day JH, Briscoe M, Rafeiro E, Chapman D, Kramer B. Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. Ann Allergy Asthma Immunol. 2001;87(6):474-481. 4. Urdaneta E, Mei-Miau W, Patel M, et al. Longitudinal analysis of regular use of cetirizine demonstrates consistent relief from symptoms of seasonal allergic rhinitis. Poster Abstract. Data on file, Johnson & Johnson Consumer Inc. 5. Lin CL, Pollack CR, Wu M, Zimmerman B, et al. Cetirizine provides long-term, consistent relief from symptoms of perennial allergic rhinitis. Poster Abstract. Data on file, Johnson & Johnson Consumer Inc. 6. Murray JJ, Nathan RA, Bronsky EA, Olufade AO, Chapman D, Kramer B. Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment. Allergy Asthma Proc. 2002;23(6):391-398.

RHINOCORT® is a licensed trademark of AstraZeneca AB.

©Johnson & Johnson Consumer Inc. 2018. All rights reserved. The third-party trademarks used herein are registered trademarks of their respective owners and not Johnson & Johnson Consumer Inc. This site is published by Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division, which is solely responsible for its contents. This website is intended for U.S. healthcare professionals only. Questions or comments? Call our Customer Care Center for Healthcare Professionals at 1-866-948-6883.